AstraZeneca PLC

Strong top-line / EPS momentum (good): - Total revenue +7% for the first 9 months of 2026; product revenue +6%. - Core EPS +14% (despite portfolio headwinds). - Ex-Farxiga & Brilinta: total revenue growth is +12%, suggesting broader portfolio resilience offset exclusivity losses. - Equity & pipeline “execution” signal: management highlighted 12 positive Phase III readouts since Feb and first approvals for 4 new medicines (incl. Etcamah in the U.S.), targeting 20 new medicines by 2030.

Headwinds clearly acknowledged (bad): - CVRM declines: Biopharmaceuticals revenue -6% QoQ/quarterly to $5.6B; CVRM -18% to $2.6B driven by expected loss of exclusivity for Farxiga/Brilinta and VBP in China. - Operational margin seasonality & China Q4 items: expects core gross margin lower in 2H due to seasonal demand for lower-margin products and year-end hospital budget capping / NRDL stock compensation effects in China. - Working capital drag: operating cash flow $10.9B, lower than prior year, with Farxiga U.S. loss of exclusivity working capital effects expected to persist through remainder of the year before normalizing.

Guidance reiterated (watch forecasts): - Company reiterated full-year outlook: Total revenue mid- to high single-digit growth and core EPS low double-digit growth. - Capex outlook: expects full-year CapEx up low-teens % vs 2025, but changed vs prior due to project starts moving into 2027. - Debt/credit posture remains a plus: net debt-to-EBITDA ~1.2x and management says they remain comfortable with current gross debt level.